
Latent Labs makes biology programmable by providing generative AI models that accelerate molecular design for health and sustainability. They build foundational deep learning models and generative AI…

Latent Labs makes biology programmable by providing generative AI models that accelerate molecular design for health and sustainability. They build foundational deep learning models and generative AI…
Founded: 2023
Founder / CEO: Dr. Simon Kohl
HQ: London; office in San Francisco
Focus: Generative AI models for molecular and protein design
Latest funding: $50M (announced Feb 13, 2025)
Computational protein design, antibody and drug candidate design, enzyme optimization, genetic engineering
2023
Biotechnology
$40,000,000
Part of a $50M total announced funding round; additional participation from other institutional and angel investors.
$10,000,000
Included in the announced $50M total alongside the Series A
“Participation from institutional investors (Radical Ventures, Sofinnova Partners, Flying Fish, Isomer, 8VC, Kindred Capital, Pillar VC) and notable technical angel investors (including Jeff Dean and Aidan Gomez)”
| Company |
|---|
Who We Are At Latent Labs, we are building frontier models that learn the fundamentals of biology. We pursue ambitious goals with curiosity and are committed to scientific excellence. Before building Latent Labs, our team co-developed DeepMind’s Nobel-prize winning AlphaFold, invented latent diffusion, and built pioneering lab data management systems as well as high throughput protein screening platforms. At Latent Labs you will be working with some of the brightest minds in generative AI and biology.
Our team is committed to interdisciplinary exchange, continuous learning and collaboration. Team offsites help us foster a culture of trust across our London and San Francisco sites.
We’re looking for innovators passionate about tackling complex challenges and maximizing positive global impact. Join us on our moonshot mission.
The Opportunity
The role will provide hands-on business development support to help close and scale strategic pharma partnerships and grow new verticals. You will take ownership of moving qualified opportunities through the deal process: researching target organisations, identifying and reaching decision-makers, developing back-channel relationships, managing follow-ups, and keeping momentum through meetings, calls, conferences, and in-person engagement. You will bring a strong pharmaceutical network, credible domain knowledge, and proven experience negotiating enterprise pharma deals, while also helping shape new commercial models for AI-for-bio partnerships. A key part of the role will be designing scalable, modular deal structures that balance emerging value and risk considerations, such as data rights, trained model weights, exclusivity, and long-term growth potential. Ultimately, this person will help turn a strong pipeline into closed partnerships, while building a repeatable sales and deal-making process for the company.
What sets you apart
Your Responsibilities
Apply We offer strongly competitive compensation and benefits packages, including:
We also offer a stimulating work environment, and the opportunity to shape the future of synthetic biology through the application of breakthrough generative models.
We welcome applicants from all backgrounds and we are committed to building a team that represents a variety of backgrounds, perspectives, and skills.
Your next opportunity is in here somewhere. Sign up to explore 70,000+ startups and their open roles. No spam. No gamification. Just jobs.
70,000+
Startups
81,000+
Open Roles
4,600+
New This Week